Hematology/Oncology Fellowship Program
At the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, we offer three-year fellowships in collaboration with Emory University School of Medicine to qualified, promising physicians. We are dedicated to providing a comprehensive program for training subspecialty fellows in pediatric hematology/oncology.

Our goal

Our goal is to train academically oriented hematologists and oncologists who will be involved in a lifetime of excellence in patient care and teaching, in addition to clinical, translational or basic research. Upon successful completion of our training program, fellows will:

• Have a thorough understanding of the pathophysiology of pediatric hematologic and oncologic disorders.
• Be competent in the clinical diagnosis and management of these disorders.
• Understand clinical trials methodology.
• Excel in a selected research interest. Our program seeks to cultivate and encourage laboratory researchers and clinical investigators.

First-year fellows maintain a continuity clinic one day each week. Second- and third-year fellows have the option of changing clinics to every two weeks and being part of outpatient clinics focused on their specific areas of interest.

Clinical rotations–first year

• Oncology ward service (three months)
• Blood and marrow transplant (BMT)—inpatient/ outpatient service (two months)
• Hematology ward (two months)
• Outpatient hematology and subspecialty clinic service (two months)
• Neuro-oncology—inpatient/outpatient service (one month)
• Lab rotation—radiation oncology, hematopathology, flow cytometry, cytogenetics, blood banking and special coagulation (one month total divided into two-week blocks)
• Research exploration (one month total divided into two-week blocks)
• Continuity clinic (one day per week)

Research–second and third year

Second- and third-year fellows are offered a variety of opportunities in clinical, translational and basic research. These opportunities are available at the Aflac Cancer Center and within specific divisions of the Emory University Department of Pediatrics.

We are devoted to training physician-scientists seeking careers in laboratory-based academic pediatric hematology/oncology. Research opportunities are performed in collaboration with faculty at the Winship Cancer Institute of Emory University, Emory School of Public Health, Georgia Institute of Technology, the Yerkes National Primate Research Center and the Centers for Disease Control and Prevention (CDC).

In addition to the laboratory-based research track, we offer a clinical research track for fellows interested in careers as clinical investigators. Fellows interested in clinical research are encouraged to apply for Emory’s Master of Science in clinical research (MSCR). We are in a unique position to offer special resources for laboratory and clinical training throughout the fellowship period for extended periods of research time, if required.

We have an individualized scholarship oversight and mentoring committee that guides each fellow through their research experience.

Research–optional fourth year

The fourth year is almost exclusively devoted to research and is available with funding to all fellows. This allows fellows to increase their skills for competitiveness in garnering future K-type or other awards for young investigators. We offer fourth-year subspecialty clinical fellowship positions in neuro-oncology and BMT. The goal of the fellowship programs is to train board-certified and board-eligible pediatric hematology/oncology graduates to effectively evaluate and manage children and teens with blood disorders, as well as benign and malignant tumors. Fellows will also become familiar with clinical and/or basic science research techniques.
PhD Program
In conjunction with the Emory Pediatric Fellowship Program, the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, we offer a unique pathway for pediatric hematology/oncology fellows to pursue a PhD during the research portion of their fellowship.

The goal of this program is to train academically oriented pediatric hematologists and oncologists for a lifetime of excellence in patient care and teaching, while also becoming research scholars with in-depth scientific training and earning a PhD in a biomedical discipline. Our program offers young pediatric hematologists and oncologists the rigorous scientific training necessary for success in today’s competitive environment, especially for trainees with limited research backgrounds.

Typical on-call schedule
- Night call takes place at home. Fellows occasionally return to the hospital to evaluate extremely ill or newly diagnosed patients.
- First-year: One in four weeknights and one weekend per month
- Second-year: Three to four weeknights and one weekend every one to two months
- Third-year: One to two weeknights per month and one weekend every six months

Didactic schedule
A variety of conferences and seminars are offered. A sample schedule is listed below. Additionally, structured teaching, ethics and research overview courses are offered throughout the year.

<table>
<thead>
<tr>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.M.</td>
<td>Core curriculum review</td>
<td>Grand rounds</td>
<td>Patient care conference</td>
<td></td>
</tr>
<tr>
<td>P.M.</td>
<td>Research conference</td>
<td>Tumor board</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional benefits of the program
Fellows receive three weeks of vacation each year. Each fellow has an educational stipend that may be used for meetings, journals or other educational expenses. Senior fellows attend additional scientific meetings based on research presentations.

Accreditation
Our program has been accredited since the 1980s and received accreditation in 2004 by the Accreditation Council for Graduate Medical Education. The Aflac Cancer Center is affiliated with Emory University, which is ranked among the top research medical schools in the country by U.S. News & World Report.

Funding
Fellows are fully funded during the three-year program. Additional years of research training, including application for the MSCR program, are available for qualified candidates.
Second-year fellows

Megan Brown, MD
megan.brown@choa.org
College: Michigan State University
Medical school: Michigan State University
Residency: Children’s Hospital Colorado

“I chose the Aflac Cancer Center and Emory for a variety of reasons. The clinical exposure and full breadth of hematologic and oncologic conditions is unmatched, and there are limitless opportunities for research and academic pursuits regardless of your field of interest. Additionally, the program leadership truly values and prioritizes fellow development and education, and the entire department is collegial and supportive with a strong focus on providing the highest quality care to our patients.”

Christina Caruso, MD
christina.caruso@choa.org
College: Boston College
Medical school: Creighton University
Residency: North Shore-Long Island

“It is important to me that I train at a large academic institution that is equally dedicated to and strong in hematology/oncology, and I have definitely found that at the Aflac Cancer Center and Emory.”

Amanda MacGregor Harrington, MD
amanda.harrington@choa.org
College: University of Georgia
Medical school: Medical College of Georgia
Residency: Tufts Medical Center

“I chose the Aflac Cancer Center and Emory because I knew it was one of the best programs in the country and would offer me a wealth of learning opportunities. Equally as important, I chose the Aflac Cancer Center and Emory because of the people who work here. I felt like this would be a place that I could thrive surrounded by people who love what they do and are always striving to provide excellent patient care. Between high patient volume, a structured learning environment with commitment to fellow education and a supportive faculty with leading experts in the field, I knew this was the right program for me.”

Rafi Kazi, MD
rafi.kazi@choa.org
College: Harvard University
Medical school: University of Arkansas
Residency: University of Rochester

“I was excited by the broad clinical opportunities and the strong research program. Also, everyone was very nice.”

Anthony Ross, MD
anthony.ross@choa.org
College: Duquesne University
Medical school: University of Pittsburgh
Residency: Children's Hospital of Pittsburgh

“I chose the Aflac Cancer Center and Emory for their well-rounded hematology/oncology training, as well as its dedication to excellent patient care and cutting-edge research.”

Third-year fellows

Ashley Eason, MD
ashley.eason@choa.org
College: University of Georgia
Medical school: Mercer University
Residency: University of Virginia

“When applying for a fellowship, I wanted to find a program that was strong in hematology/oncology that also provided ample research opportunities. During my first few months, the Aflac Cancer Center and Emory have provided that and more with supportive faculty, engaging teaching sessions and broad clinical exposure.”

Dan Runco, MD
daniel.runco@choa.org
College: Creighton University
Medical school: Loyola University Chicago Stritch School of Medicine
Residency: Riley Hospital for Children at Indiana University Health

“The Aflac Cancer Center and Emory have the best of all worlds and this program pushes you to develop and pursue your own interests—not to fit into someone else’s mold. There are clinical and research opportunities in all aspects of hematology/oncology and I felt like if I trained here, there was no door that was closed to me.”

Jenny Shim, MD
jenny.shim@choa.org
College: Siena College
Medical school: Albany Medical College
Residency: University of Texas Southwestern Dallas Medical Center

“What I love about the Aflac Cancer Center and Emory are their infinite potential to grow and the fact that it continues to grow in patient care and research. We have a wonderful faculty group that provides well-rounded and personal mentorship. The research opportunities and career development with fourth-year support in hematology/oncology is invaluable.”

Sherri Smart, MD, PhD
sheri.smart@choa.org
College: University of Central Arkansas
Medical school: University of Arkansas
Residency: University of Cincinnati

“The Aflac Cancer Center and Emory are a strong academic center with equal focus in hematology/oncology and ample research opportunities in clinical, translational and basic science. During my interview, the biggest thing that stood out in my mind was how happy the fellows, faculty and staff were. I can tell you now that what you see on the surface holds true. We truly are a family.”

Michael White, MD
michael.white@choa.org
College: Harding University
Medical school: University of Texas Southwestern Medical School
Residency: Vanderbilt University

“I chose to train at the Aflac Cancer Center and Emory because they are one of the largest and most robust hematology/oncology centers in the country and the people here are top notch. The research and professional opportunities are endless here, and I could not feel more supported by our leadership. I’m thrilled to be in Atlanta.”
The two-campus model provides more depth to a fellow’s clinical experience. I feel that our learning is enhanced by exposure to the academic and private practice settings.”

~Jonathan Metts, MD
our team and interests

Leadership

Division Director
Douglas K. Graham, MD, PhD
Professor and Director, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta
Associate Professor of Pediatrics, Emory University School of Medicine
Associate Director, Fellowship Program
Glen Lew, MD

Dr. Graham is an NIH investigator with an active laboratory focusing on developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, non-small cell lung cancer and glioblastoma. He has served in multiple leadership roles with the American Society of Pediatric Hematology/Oncology and has an appointment as a full member of the NIH Molecular and Cellular Hematology Study Section.

Fellowship Program

William Woods, MD
Director, Fellowship Program
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta
Professor and Director Emeritus, Emory University School of Medicine

Kathryn Sutton, MD
Associate Director, Fellowship Program
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta
Assistant Professor of Pediatrics, Emory University School of Medicine

Glen Lew, MD
Associate Director, Fellowship Program
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta
Associate Professor of Pediatrics, Emory University School of Medicine

BMT

Lakshmanan Krishnamurti, MD, Director of BMT: Newborn screening and counseling for hemoglobinopathies, novel approaches to hematopoietic stem cell transplantation for hemoglobinopathies, mechanisms of vascular complications of sickle cell disease and bioinformatics systems in clinical care and research in sickle cell disease

Kathryn Leung, MD, Clinical Director of BMT: Pediatric bone marrow or stem cell transplant for patients with bone marrow failure due to multiple causes and for patients with hemoglobinopathies

Shanmuganathan Chandrakasan, MD: Hematopoietic cell transplant and gene therapy for immune deficiency, immune deficiency, immune dysregulation and hemophagocytic lymphohistiocytosis (HLH), immunohematology and bone marrow failure, stem cell biology

Staci Arnold, MD: Health outcomes, cost benefit analysis, comparative effectiveness research for sickle cell disease and bone marrow failure syndromes

Mina-Ohui Quarmyne, MbChB: Thrombosis treatment and prevention

Marianne E. Yee, MD, MSc: Clinical research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease

Medical Genomics

Edwin Horwitz, MD, PhD: Transplantation of marrow cells and mesenchymal stromal cells (MSCs) to treat cancer and genetic disorders of childhood

Muna Qayed, MD, MSci: Incorporation of novel agents into the treatment of relapsed solid tumors, improving current treatments for patients with high-risk disease, including autologous stem cell transplant and developing more effective prophylaxis and treatment against GVHD in patients undergoing allogeneic BMT

Elizabeth O. Stenger, MD: BMT for nonmalignant disease, tolerance and GVHD prevention and treatment

Benjamin Watkins, MD: Clinical trials and research in developing more effective prophylaxis and treatment against GVHD in patients undergoing allogeneic BMT

Hematology

General hematology

Jeanne M. Boudreaux, MD, Clinical Director of Hematology: Thalassemias, bone marrow failure syndromes, hemolytic anemias and white cell disorders

Staci Arnold, MD: Health outcomes, cost benefit analysis, comparative effectiveness research for sickle cell disease and bone marrow failure syndromes

Glaivy Batsuli, MD: Basic and translational research in hemophilia A and inhibitors

Carolyne M. Bennett, MD: Platelet disorders, including immune thrombocytopenic purpura (ITP)

Michael A. Briones, DO: Vascular anomalies, hystiocytic disorders, general hematology and inherited bone marrow failure syndrome

Shanmuganathan Chandrakasan, MD: Hematopoietic cell transplant and gene therapy for immune deficiency, immune deficiency, immune dysregulation and HLH, immunohematology and bone marrow failure, stem cell biology

Satheesh Chonat, MD: Red cell enzyme and red membrane deficiencies

Kavita Patel, MD: Thrombosis treatment and prevention

Maa-Ohui Quarmyne, MbChB: Sickle cell disease and thalassemias, stroke prevention in sickle cell disease and outcomes in sickle cell disease

Marianne E. Yee, MD, MSc: Clinical research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease

Hemophilia/thrombosis

Robert Sidonio Jr., MD, Clinical Director of Hemostasis and Thrombosis: von Willebrand disease, particularly in the setting of menorrhagia

Pete Lollar, MD, Research Director of Hemostasis: Development of novel recombinant Factor VIII molecules for use in preventing and treating hemophilia patients with inhibitors and basic research in biosynthesis and expression of Factor VIII

Glaivy Batsuli, MD: Basic and translational research in hemophilia A and inhibitors

Carolyne M. Bennett, MD: Platelet disorders, including ITP

Wei Deng, PhD: Protein interactions that contribute to the hemostasis and thrombosis to investigate how these interactions are disturbed in patients with bleeding disorders and to search for effective therapeutic approaches

Renhao Li, PhD: Development of novel reagents to improve bleeding diagnostics and platelet storage
Shannon Meeks, MD: Basic and translational research in hemophilia A and inhibitors
Kavita Patel, MD: Thrombosis treatment and prevention
Brian Petrich, PhD: Regulation of platelet integrin signaling in hemostasis, and thrombosis and cell adhesion mechanisms in vascular disease and thrombosis
Yingchun Wang, MD, PhD: Clinical basic and translational research in hemophilia and thrombosis
Gary Woods, MD: Venous thromboembolism, especially in chronic disease like sickle cell disease and pediatric heart disease, and coagulation disorders

Sickle cell disease

Clinton H. Joiner, MD, PhD, Director of Hematology: Red cell physiology, specifically cation transport and volume regulation and their perturbation in sickle cell disease
R. Clark Brown, MD, PhD, Clinical Director: Targeted therapies for thalassemia and sickle cell disease
Beatrice Gee, MD, Clinical Director: Clinical research in sickle cell disease
Marianne E. Yee, MD, MSc, Clinical Director: Clinical research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease
Peter A. Lane, MD, Program Director: Newborn screening, health outcomes and clinical trials in sickle cell disease
David R. Archer, PhD: Hematopoietic stem cell transplant for genetic disease, particularly sickle cell disease and use of stem cells in regenerative medicine
Nitya Bakshi, MD: Pain in sickle cell disease, including psychophysical pain phenotyping in pediatric patients with sickle cell disease and development and validation of electronic pain diaries for children with sickle cell disease
Carlton D. Dampier, MD: Clinical trials in sickle cell disease, measurement science of patient- and parent-reported outcomes and symptom management in sickle cell disease, particularly pain
Elissa Hardy, PhD: Effects of applied electricity with hemostasis
Anne G. James-Herry, MD: Clinical research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease

Transfusion medicine

Cassandra D. Josephson, MD: Clinical transfusion medicine and blood safety in hemophilia, sickle cell disease, neonatology and open heart surgery

Leukemia and lymphoma

Sharon Castellino, MD, Director of Leukemia and Lymphoma: Hodgkin lymphoma and survivorship
Daniel Wechsler, MD, PhD, Director of Oncology: Infant leukemias, pathogenesis of poor prognosis CALM-associated leukemias and MYC antagonism in neuroblastoma
Douglas K. Graham, MD, PhD, Division Director: Developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, nonsmall cell lung cancer and glioblastoma
Kevin D. Bunting, PhD, Research Director of Leukemia and Lymphoma: Studies of normal cytokine signaling in hematopoiesis and dysregulated signaling associated with inflammation and cancer
D. John Bergsagel, MD: Clinical trials in leukemia and lymphoma
Deborah DeRyckere, PhD: Preclinical development of novel small molecule MerTK inhibitors for oncology applications, TAM-family receptor tyrosine signaling and biology, murine xenograft models of acute leukemia
Kavita Dhodapkar, MD, PhD: Mechanisms of immune regulation, in the context of autoimmunity as well as tumor immunity, in-vivo effects of immune checkpoint blocking therapies, including the role for B cells in development of autoimmunity following treatment with these agents, methods to boost anti-tumor immunity using dendritic cells
Lubing Gu, MD: Molecular mechanisms of drug resistance in childhood cancer and leukemia
Curtis Henry, PhD: Research focuses on understanding how chronic inflammation associated with aging and obesity impacts leukemia development and therapeutic responses
Glen Lew, MD: Study chair of COG Phase III trial for relapsed acute lymphoblastic leukemia (ALL) and etiology, treatment and outcomes in childhood ALL
Tamara Miller, MD, MSCE: Leukemia and lymphoma, general oncology and adverse events
Katherine Minson, MD: Novel therapeutic targets in AML
Melinda Pauly, MD: Relationship of the BCL-2 family of proteins within the intrinsic apoptotic pathway to members of the autophagy pathway
Christopher Porter, MD: Cancer genetics and leukemia research
Cheng-Kui Qu, MD, PhD: Cell signaling and metabolic regulation of hematopoietic stem cells focusing on the role of protein and lipid phosphates in normal hematopoietic cell development and leukemogenesis, and development of novel therapeutics for phosphates-associated blood disorders, such as juvenile myelomonocytic leukemia
Sunil Raikar, MD: Development of novel chimeric antigen receptor (CAR) natural killer cells against T-cell malignancies
Himalee Sabnis, MD, MS: Biology of acute myeloid leukemia (AML), signaling pathways in leukemia cells and new therapeutic agents in AML
Zhengqi Wang, PhD: Study of STAT5 and its function in signaling mechanisms in leukemogenesis, hematopoietic stem cell biology and transplant
William G. Woods, MD: Clinical trials within COG in myeloid leukemia
Dan Yan, PhD: The role of MerTK on human non-small-cell lung cancer
Muxiang Zhou, MD: Signaling pathways and regulators of apoptosis relating to drug resistance in ALL
**Palliative care**
Katharina Brock, MD, MS: Clinical research in palliative care, assessing, and improving access and quality of pediatric palliative care within oncology, and the metrics and outcomes associated with a pediatric supportive care clinic

**Solid tumors**
Thomas A. Olson, MD, **Clinical Director of Solid Tumors**: Committee chair for COG germ cell disease, clinical trials in germ cell tumors, retinoblastoma and bone tumors
Thomas Cash, MD, MSc: Outcomes and epidemiology in rare pediatric tumors; the role of ezrin and tumor necrosis in patients with Ewing Sarcoma; and innovative therapy and Phase I and II trials
Bradley A. George, MD: Solid tumors and histiocytosis
Kelly Goldsmith, MD: Basic and translational research of neuroblastoma, with a primary focus on mechanisms of therapy resistance
Sarah Mitchell, MD: Solid tumors and rare tumors, underlying hereditary cancer syndrome
Robert Schnopp, MD, PhD: Research with a major emphasis on high-risk neuroblastoma and rhabdomyosarcoma employing a number of techniques, including cell and molecular biology, animal modeling, interrogation of genomic datasets with clinical annotation and functional genomics
Kathryn Sutton, MD: Clinical researcher in solid tumors, including sarcomas, rare tumors and histiocytosis

**Neuro-oncology**
Tobey J. MacDonald, MD, **Director of Neuro-oncology**: Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGFR) signaling
Dolly Aguilera, MD: Development of Phase I and II clinical trials for children with recurrent brain tumors
Robert C. Castellino, MD: Pediatric neuro-oncology, interactions between p53/Hedgehog and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development
Delores Hambardzumyan, PhD: Investigating the role of the brain microenvironment in how it contributes to pediatric and adult glioblastoma growth and response to therapy
Anna J. Janss, MD, PhD: Phase I COG clinical trials and innovative therapeutics for brain tumors
Anna M. Kenney, PhD: How Sonic hedgehog and interacting signal transduction pathways control normal and neoplastic development within the cerebellum
Claire M. Mazewski, MD: Principal investigator of COG high-risk medulloblastoma trial for young children, clinical trials, innovative therapeutics and late effects studies for children with brain tumors

**Hospitalists**
Joanna Newton, MD: Racial and ethnic disparities in pediatric AML outcomes, and expression of CD36 and the presence of cytoplasmic granules in blasts predicts poor prognosis in children with B-lymphoblastic leukemia

**Psychology and neuropsychology**
James Klosky, PhD, **Director of Psychology**: Childhood cancer psychology
Grace Feng, PhD: Acquired brain injury and clinical trials for late effects
Lisa Ingerski, PhD: Childhood psychology

**Acquired brain injury and clinical trials for late effects**
Grace Fong, PhD: Childhood psychology

**Childhood cancer psychology**
James Klosky, PhD, Director of Psychology:

**Psychology and neuropsychology**
B-lymphoblastic leukemia
CD36 and the presence of cytoplasmic granules in blasts predicts poor prognosis in children with

**Racial and ethnic disparities in pediatric AML outcomes, and expression of**
Joanna Newton, MD:

**normal and neoplastic development within the cerebellum**
Anna M. Kenney, PhD:

**Phase I COG clinical trials and innovative therapeutics for brain tumors**
Anna J. Janss, MD, PhD:

**How Sonic hedgehog and interacting signal transduction pathways control**
Claire M. Mazewski, MD:

**Investigating the role of the brain microenvironment in how it contributes to pediatric and adult glioblastoma growth and response to therapy**
Delores Hambardzumyan, PhD:

**Development of Phase I and II clinical trials for children with recurrent brain tumors**
Dolly Aguilera, MD:

**Pediatric neuro-oncology, interactions between p53/Hedgehog and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development**
Robert C. Castellino, MD:

**Investigating the role of the brain microenvironment in how it contributes to pediatric and adult glioblastoma growth and response to therapy**
Delores Hambardzumyan, PhD:

**Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGFR) signaling**
Tobey J. MacDonald, MD, **Director of Neuro-oncology**:

**Development of Phase I and II clinical trials for children with recurrent brain tumors**
Dolly Aguilera, MD:

**Pediatric neuro-oncology, interactions between p53/Hedgehog and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development**
Robert C. Castellino, MD:

**Investigating the role of the brain microenvironment in how it contributes to pediatric and adult glioblastoma growth and response to therapy**
Delores Hambardzumyan, PhD:

**Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGFR) signaling**
Tobey J. MacDonald, MD, **Director of Neuro-oncology**:
Developmental therapeutics

Jason Fangusaro, MD, Director of Developmental Therapeutics: Development of early phase clinical trials, novel therapeutics and relevant biologic correlates in an effort to improve survival outcomes and minimize toxicities. Within pediatric brain tumors, his research has focused on three main areas: low grade gliomas, central nervous system germ cell tumors and immunotherapy.

Melinda Pauly, MD, Clinical Director of Developmental Therapeutics: Relationship of the BCL-2 family of proteins within the intrinsic apoptotic pathway to members of the autophagy pathway.

Dolly Aguilera, MD: Development of Phase I and II clinical trials for children with recurrent brain tumors.

Thomas Cash, MD, MSc: Outcomes and epidemiology in rare pediatric tumors; the role of ezrin and tumor necrosis in patients with Ewing sarcoma; innovative therapy and Phase I and Phase II trials.

Robert C. Castellino, MD: Pediatric neuro-oncology, interactions between p53/Hedgehog/and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development.

Kelly Goldsmith, MD: Basic and translational research of neuroblastoma, with a primary focus on mechanisms of therapy resistance.

Tobey J. MacDonald, MD: Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of PDGFR signaling.

Himalee Sabnis, MD, MS: Biology of AML, signaling pathways in leukemic cells and new therapeutic agents in AML.

Ranked among the fastest-growing metro areas in the country,* Atlanta combines Southern hospitality with the amenities of any world-class city. More than 6.5 million metro Atlanta residents enjoy the city’s rich history and cultural diversity. Whether you are a sports fanatic, history buff or have a love of the arts, Atlanta offers something for everyone.

Why Atlanta?

- Cost of living is less expensive than other major cities**
- Hartsfield-Jackson Atlanta International Airport is the world’s busiest airport.
- Atlanta is within a two-hour flight of 80 percent of all U.S. cities.
- Twenty-six companies headquartered in metro Atlanta are among the 2018 Fortune 1000, of which 15 are also ranked in the 2018 Fortune 500.
- Museums, theaters and eclectic shopping areas.
- Professional sports teams, including the Atlanta Falcons, Atlanta Braves, Atlanta Hawks and Atlanta United.
- Vast number of restaurant options, including a wealth of ethnic cuisines.
- Seasonal climate suitable for outdoor activities year-round.
- Within driving distance of the mountains and ocean.

Contact us

Visit choa.org/aflacfellowship for more information.

Email Angie Graves at angie.graves@emory.edu.
Email William Woods, MD, at william.woods@choa.org.

All applications are accepted through ERAS. A requirements checklist is available online.

*forbes.com

**metroatlantachamber.com

Hughes Spalding is owned by Grady Health System and managed by HSOC Inc., an affiliate of Children’s Healthcare of Atlanta.

Some physicians and affiliated healthcare professionals on the Children’s Healthcare of Atlanta team are independent providers and are not our employees.